South San Francisco / L. A. / Indianapolis / Gaithersburg / Hoboken / Seattle / Thielens / Cambridge / /
Company
Alexion / Novartis / Macmillan Publishers Limited. / Amgen / Low Low Ab / Genentech / GlaxosmithKline / Cellular Resources / Bristol-Myers squibb / IgG / Bayer / Berkowitz S. A. / Eli Lilly and Company / Biogen Idec / Commercialization Merck & Co. / Rathore A. S. / Genzyme / Pfizer / MedImmune / Merck & Co. Union / Abs Therapeutic Ab / Elite Pharmaceuticals Inc. / /
Country
United States / / /
Event
Product Issues / FDA Phase / Product Recall / /
Facility
C1 complex / FcγRIII complex / /
IndustryTerm
therapy for diffuse large B-cell lymphoma / neceseukaryotic systems / manufacturing process / manufacturing experience / as cancer therapeutics / manufacturing / antibody products / manufacturing practice / biopharmaceutical industry / glycoprotein pharmaceutical / antibody technology / antibody manufacturing / manufacturing consistency / glycosylation site / treatment of various diseases / potential / web version / /
MedicalCondition
tumour necrosis / lymphoma cell lines / follicular lymphoma / rheumatoid arthritis / non-Hodgkin’s lymphoma / Multiple sclerosis / human multiple myeloma / primary operable breast tumors / breast cancer / tumor / autoimmune disorders / Japanese encephalitis virus / Cancer / J. Cancer / ulcerative colitis / juvenile idiopathic arthritis / diseases / chronic lymphocytic leukaemia / Cetuximab-induced anaphylaxis / acute myeloid leukemia / neu-positive metastatic breast cancer / systemic lupus erythematosus / lymphoma / colorectal cancer / spondylitis / chronic lymphocytic leukemia / III Low Allergic asthma ADcc / psoriatic arthritis / arthus reaction / rsv infection / crohn’s disease / diffuse large B-cell lymphoma / tumour / inflammation / periodic syndrome / /
MedicalTreatment
radiotherapy / immunotherapy / chemotherapy / cancer therapeutics / /
Organization
FDA / Food and Drug Administration / /
Person
Rong Jiang / Bhavin Parekh / Anthony Mire-Sluis / Thomas Arroll / Shan Chung / Kimberly May / Mark Schenerman / Xu-Rong Jiang / Robert Strouse / Svetlana Bergelson / /
Advances in the assessment and control of the effector functions of therapeutic antibodies